Search

Displaying results 2971 - 2980 of 8517 in total
  1. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.

  2. Drug

    Biguanide

    go.drugbank.com/drugs/DB13100
    ApprovedInvestigationalWithdrawn

    Biguanide has been investigated for the treatment of Diabetes Mellitus.

  3. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  4. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  5. Drug

    Varegacestat

    go.drugbank.com/drugs/DB13126
    Investigational

    BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.

  6. Drug

    Betulinic Acid

    go.drugbank.com/drugs/DB12480
    ApprovedWithdrawn

    Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.

  7. Drug

    Stavudine

    go.drugbank.com/drugs/DB00649
    ApprovedInvestigational

    A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

  8. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]

  9. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.

  10. Drug

    Anumigilimab

    go.drugbank.com/drugs/DB16359
    Investigational

    [A225626] It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.[L27516]